Description: KARPAS 1718 is derived from the peripheral blood of a patient diagnosed with transformed splenic lymphoma with villous lymphocytes

Also Known As:

Species: Human

Tissue: Splenic Lymphoma

Growth Properties: Suspension

Morphology: Single round to polymorphic cells growing in suspension

Growth Medium: RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Subculturing Procedure: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 100,000 cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 100,000 cells/ml, 5% CO2, 37°c. For cryopreservation of KARPAS 1718, freeze at approximately 2 x 107 cells/ml in 90% FBS + 10% DMSO.

Release Conditions: Yes – commercial organisations are required to complete the ‘Cell Line Release Authorisation for Research Use in Commercial Organisations’ release conditions form.

Depositor: Dr Abraham Karpas, Department of Haematology, MRC Centre, Hills Road, Cambridge, UK

Originator: Yes

References: Ota et al., 2004 Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma. Cancer Research 64: 3087-3095. (PMID: 15126345).

Hyperlink to ECACC Cell Line Data Sheet: 08072401